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Erratum
Benefit of a Second Opinion for Lung Cancer: No Recurrent Disease, but Infection: Erratum
In the article that appeared on page e6 of the August 2012 issue of the Journal of Thoracic Oncology, the names of all authors appeared incorrectly. 
The correct names are:
Romane M. Schook, MD, Egbert F. Smit, MD, PhD, Pieter E. Postmus, MD, PhD, Koen J. Hartemink, MD, PhD, and Marinus A. Paul, MD, PhD
Reference:
Schook RM, Smit EF, Postmus PE, Hartemink KJ, Paul MA. Benefit of a Second Opinion for Lung Cancer: No Recurrent Disease, but Infection. J Thorac 
Oncol. 2012;7:e6–e7.
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Erratum
Long-Term Surveillance of Ground-Glass Nodules: Evidence from the MILD Trial: Erratum
In the article that appeared on page 1541 of the October 2012 issue of the Journal of Thoracic Oncology, the names of all authors appeared incorrectly. 
The correct names are:
Mario Silva, MD, Nicola Sverzellati, MD, PhD, Carmelinda Manna, MD, Giulio Negrini, MD, Alfonso Marchianò, MD, Maurizio Zompatori, MD, Cristina 
Rossi, MD, and Ugo Pastorino, MD
Reference:
Silva M, Severzellati N, Manna C, Negrini G, Marchianò A, Zompatori M, Rossi C, Pastorino U. Long-Term Surveillance of Ground-Glass Nodules: 
Evidence from the MILD Trial. J Thorac Oncol. 2012;7:1541–1546.
Erratum
First-Line Gefitinib in Patients Aged 75 or More with Advanced Non-Small Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Mutations: 
NEJ 003 Study: Erratum
In the article that appeared on page 1417 of the September 2012 issue of the Journal of Thoracic Oncology, the name of the last author was spelled incor-
rectly. The correct spelling is Akihiko Gemma, PhD.
Reference:
Maemondo M, Minegishi Y, Inoue A, Kobayashi K, Harada M, Okinaga S, Morikawa N, Oizumi S, Tanaka T, Isobe H, Kudoh S, Hagiwara K, Nukiwa T, 
Gemma A. First-Line Gefitinib in Patients Aged 75 or More with Advanced Non-Small Cell Lung Cancer Harboring Epidermal Growth Factor Receptor 
Mutations: NEJ 003 Study. J Thorac Oncol. 2012;7:1417–1422.
